A Multicenter Randomised Study Comparing the Efficacy of PegIFN-alfa2a Plus Placebo vs. PegIFN-alfa2a Plus Tenofovir for the Treatment of Chronic Delta Hepatitis-The Hep-Net International Delta Hepatitis Interventional Trial II (HIDIT-II).

Trial Profile

A Multicenter Randomised Study Comparing the Efficacy of PegIFN-alfa2a Plus Placebo vs. PegIFN-alfa2a Plus Tenofovir for the Treatment of Chronic Delta Hepatitis-The Hep-Net International Delta Hepatitis Interventional Trial II (HIDIT-II).

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Oct 2016

At a glance

  • Drugs Tenofovir disoproxil fumarate (Primary) ; Peginterferon alfa-2a
  • Indications Hepatitis D
  • Focus Therapeutic Use
  • Acronyms HIDIT-2; HIDIT-II
  • Most Recent Events

    • 03 Nov 2013 Results of a 96-week analysis presented at the 64th Annual Meeting of the American Association for the Study of Liver Diseases.
    • 03 Nov 2013 Primary endpoint 'Viral-load' has not been met.
    • 13 Nov 2012 Interim results presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top